M1774 in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
Status:
Not yet recruiting
Trial end date:
2026-09-03
Target enrollment:
Participant gender:
Summary
This is an Open-label, multicenter clinical study conducted in two Phases to establish the
efficacy, safety, tolerability, and pharmacokinetics of the ataxia telangiectasia mutated and
Rad3-related protein kinase (ATR) inhibitor M1774 in Combination with Cemiplimab in
Participants with Non-Squamous Non-Small Cell Lung Cancer (nsqNSCLC) that has Progressed on
Prior Anti-PD-(L)1 and Platinum-based Therapies